Dept. of Surgery, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA.
Am J Physiol Gastrointest Liver Physiol. 2010 Feb;298(2):G167-76. doi: 10.1152/ajpgi.00385.2009. Epub 2009 Nov 19.
The glutamic acid derivative thalidomide is a transcriptional inhibitor of TNF-alpha but is also known to affect human blood vessels, which may underlie its teratogenicity. Thalidomide has been used in the treatment of refractory Crohn's disease (CD), but the therapeutic mechanism is not defined. We examined the effect of thalidomide on primary cultures of human intestinal microvascular endothelial cells (HIMEC), the relevant endothelial cell population in inflammatory bowel disease (IBD), to determine its effect on endothelial activation, leukocyte interaction, and VEGF-induced angiogenesis. HIMEC cultures were pretreated with thalidomide before activation with either TNF-alpha/LPS or VEGF. A low-shear-stress flow adhesion assay with either U-937 or whole blood was used to assess HIMEC activation following TNF-alpha/LPS, and a Wright's stain identified adherent leukocytes. Expression of cell adhesion molecules (E-selectin, intercellular adhesion molecule-1, vascular cell adhesion molecule-1) was assessed using radioimmunoassay. Effects of thalidomide on NF-kappaB activation, cyclooxygenase (COX)-2, and inducible nitric oxide synthase (iNOS) expression in TNF-alpha/LPS-activated HIMEC were determined by RT-PCR and Western blotting. Thalidomide blocked adhesion of both U-937 and whole blood leukocytes by 50% in HIMEC, inhibiting binding of all classes of leukocytes. Thalidomide also blocked NF-kappaB and cell adhesion molecule expression in HIMEC. In marked contrast, thalidomide did not affect either iNOS or COX-2 expression, two key molecules that play a role in the downregulation of HIMEC activation. VEGF-induced HIMEC transmigration, growth, proliferation, tube formation, and Akt phosphorylation were significantly inhibited by thalidomide. In summary, thalidomide exerted a potent effect on HIMEC growth and activation, suggesting that it may also function via an endothelial mechanism in the treatment of CD.
谷氨酸衍生物沙利度胺是 TNF-α 的转录抑制剂,但也已知会影响人体血管,这可能是其致畸性的基础。沙利度胺已用于治疗难治性克罗恩病(CD),但其治疗机制尚未确定。我们研究了沙利度胺对原代培养的人肠道微血管内皮细胞(HIMEC)的影响,HIMEC 是人肠道炎症性肠病(IBD)中相关的内皮细胞群体,以确定其对内皮细胞激活、白细胞相互作用和 VEGF 诱导的血管生成的影响。在激活 TNF-α/LPS 或 VEGF 之前,用沙利度胺预处理 HIMEC 培养物。用 U-937 或全血进行低剪切力流黏附测定,以评估 TNF-α/LPS 后 HIMEC 的激活,Wright 染色鉴定黏附的白细胞。用放射免疫测定法评估细胞黏附分子(E-选择素、细胞间黏附分子-1、血管细胞黏附分子-1)的表达。通过 RT-PCR 和 Western 印迹法确定沙利度胺对 TNF-α/LPS 激活的 HIMEC 中 NF-κB 激活、环氧化酶(COX)-2 和诱导型一氧化氮合酶(iNOS)表达的影响。沙利度胺在 HIMEC 中抑制 50%的 U-937 和全血白细胞黏附,抑制所有白细胞类别的结合。沙利度胺还抑制 HIMEC 中的 NF-κB 和细胞黏附分子表达。相比之下,沙利度胺对 iNOS 或 COX-2 表达没有影响,这两种关键分子在下调 HIMEC 激活中起作用。VEGF 诱导的 HIMEC 迁移、生长、增殖、管形成和 Akt 磷酸化均被沙利度胺显著抑制。总之,沙利度胺对 HIMEC 的生长和激活产生了强大的影响,这表明它在治疗 CD 中也可能通过内皮机制发挥作用。